纤溶酶原激动抑制剂-1基因4G/5G多态性与冠心病  

The 4G/5G Polymorphism of the Plasminogen Activator Inhibitor-1 Gene in Patients with Coronary Heart Disease

作　　者：傅研[1] 王旭东[1] 翟艳玲[1] 樊峥[2] 杨玲 朱宇清[1] 祁雅慧[2] 赵相印[1] 

机构地区：[1]首都医科大学附属北京同仁医院急诊科 [2]首都医科大学实验中心

出　　处：《首都医科大学学报》2001年第2期119-122,共4页Journal of Capital Medical University

摘　　要：采用特异性引物多聚合酶链式反应方法 ,检测了 1 2 3例冠心病患者和 1 72例健康对照者的纤溶酶原激动抑制剂 1 (PAI 1 )基因 ,并同时测定血液PAI 1质量浓度和活性 ,体质量指数、胆固醇和三酰甘油 ,探讨了PAI 1基因4G/5G多态性与冠心病的相关性。结果显示 ,冠心病组的缺失型纯合子 4G/4G型 ( 47.2 %)明显多于对照组 ( 2 2 .1 %,P <0 .0 5) ,4G/4G组的PAI 1质量浓度〔( 40 .87± 0 .99) μg/L)〕和PAI活性〔( 750± 350 )U/L〕均高于 5G/5G组〔( 38.1 4± 1 .0 ) μg/L ,( 650± 2 70 )U/L ,P <0 .0 5〕。提示PAI 1基因 4G/5G多态性与PAI 1质量浓度及活性具有相关性 。WT5BZ]To investigate the relationship between 4G/5G polymorphism of the plasminogen activator inhibitor 1(PAI 1) gene and coronary heart disease(CHD), genotype at this polymorphism was determined in 123 cases with CHD and 172 controls by polymerase chain reaction using the allele specific primers. Plasma PAI 1 antigen level, PAI activity, cholesterol and triglyceride were measured and body mass index was calculated from all the subjects. The group of CHD had a high number of homozygotes for the deleted allele(4G/4G) of the PAI 1 gene compared with the control(47.2% vs 22.1%, P < 0.05 ). Mean plasma PAI 1 antigen level and PAI activity varied significantly among the 3 genotypes, being higher in 4G/4G subjects than in 5G/5G subjects 〔(40.87±0.99) μg/L〕 vs 〔(38.14±1.0) μg/L〕, 〔(750±350) U/L〕 vs (650±270) U/L, P <0.05). The PAI 1 4G/5G polymorphism correlated with PAI 1 antigen level to some extent accounts for the development of CHD.

关 键 词：冠心病 纤溶酶原激动抑制剂-1 基因多态性 

分 类 号：R541.4[医药卫生—心血管疾病]